Peter Rossing, EASD 2022: The effect of semaglutide on risk of MACE by baseline kidney function: SUSTAIN 6 and PIONEER 6 post hoc analysis
SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of MACE by baseline kidney function. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University of Copenhagen, Copenhagen, Denmark) discusses SUSTAIN 6 and PIONEER 6Â studies and post-hoc analyses and the effect of semaglutide across the range of kidney function.
The abstract entitled: ‘Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
Questions:
- What did the SUSTAIN 6 and PIONEER 6 studies tell us about the effect of semaglutide on major adverse cardiovascular events (MACE)? (0:22)
- What were the aims and design of the SUSTAIN 6 and PIONEER 6 post-hoc analysis you are presenting? (0:46)
- How did baseline kidney function affect the risk of MACE in participants of SUSTAIN 6 and PIONEER 6? (1:27)
- What was the effect of semaglutide across the range of kidney function? (2:01)
Disclosures: Peter Rossing is a consultant for Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, MSD, Novo Nordisk and Sanofi and discloses grant/research support from AstraZeneca and Novo Nordisk.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
